Home
MYGN
MYGN News

Latest Myriad Genetics Inc. (MYGN) News on June 21, 2025

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

Zacks

5 days ago

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

3 Hyped Up Stocks Skating on Thin Ice

StockStory

8 days ago

3 Hyped Up Stocks Skating on Thin Ice

3 Reasons to Avoid MYGN and 1 Stock to Buy Instead

StockStory

15 days ago

3 Reasons to Avoid MYGN and 1 Stock to Buy Instead

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

Zacks

16 days ago

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

3 Stocks Under $10 in the Doghouse

StockStory

16 days ago

3 Stocks Under $10 in the Doghouse

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

GlobeNewswire

18 days ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

GlobeNewswire

19 days ago

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

3 Cash-Burning Stocks Facing Headwinds

StockStory

22 days ago

3 Cash-Burning Stocks Facing Headwinds

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

Insider Monkey

25 days ago

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

GlobeNewswire

25 days ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory

25 days ago

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

3 Small-Cap Stocks with Questionable Fundamentals

StockStory

a month ago

3 Small-Cap Stocks with Questionable Fundamentals

MT Newswires

a month ago

Myriad Genetics Shares Fall After Downgrade From Scotiabank

Spotlight On 3 Penny Stocks With Market Caps Under $500M

Simply Wall St.

a month ago

Spotlight On 3 Penny Stocks With Market Caps Under $500M

MT Newswires

a month ago

Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20

Argus Research

a month ago

MYGN: Raising target price to $4.00

MT Newswires

a month ago

Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating

MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp

StockStory

a month ago

MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

GlobeNewswire

a month ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Argus Research

a month ago

MYGN: Lowering target price to $3.00

3 of Wall Street’s Favorite Stocks in Dangerous Territory

StockStory

a month ago

3 of Wall Street’s Favorite Stocks in Dangerous Territory

Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

Insider Monkey

a month ago

Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

MT Newswires

a month ago

Myriad Genetics Shares Drop After Downgrade From Wolfe Research

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Zacks

a month ago

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Simply Wall St.

a month ago

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

MT Newswires

a month ago

Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

GlobeNewswire

a month ago

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Why Myriad Genetics (MYGN) Stock Is Down Today

StockStory

a month ago

Why Myriad Genetics (MYGN) Stock Is Down Today

MT Newswires

a month ago

UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

Zacks

a month ago

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

MT Newswires

a month ago

Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22

Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...

GuruFocus.com

a month ago

Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...

Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a month ago

Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

StockStory

a month ago

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a month ago

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

GlobeNewswire

a month ago

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

StockStory

2 months ago

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

3 Unprofitable Stocks Walking a Fine Line

StockStory

2 months ago

3 Unprofitable Stocks Walking a Fine Line

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

StockStory

2 months ago

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

GlobeNewswire

2 months ago

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire

2 months ago

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

GlobeNewswire

2 months ago

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

3 Healthcare Stocks That Concern Us

StockStory

2 months ago

3 Healthcare Stocks That Concern Us

Argus Research

2 months ago

MYGN: What does Argus have to say about MYGN?

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Zacks

2 months ago

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

GlobeNewswire

2 months ago

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Argus Research

2 months ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics price target lowered to $9 from $11 at BofA

TipRanks

2 months ago

Myriad Genetics price target lowered to $9 from $11 at BofA

MT Newswires

2 months ago

Guggenheim Downgrades Myriad Genetics to Neutral From Buy

Argus Research

2 months ago

MYGN: Lowering target price to $8.00

Myriad Genetics Announces Inducement Awards

GlobeNewswire

2 months ago

Myriad Genetics Announces Inducement Awards

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

GlobeNewswire

2 months ago

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Argus Research

3 months ago

MYGN: Lowering target price to $9.00

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

Zacks

3 months ago

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Argus Research

3 months ago

MYGN: What does Argus have to say about MYGN?

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

StockStory

3 months ago

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

StockStory

3 months ago

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory

3 months ago

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

MT Newswires

3 months ago

Myriad Genetics Shares Rise After Upgrade From Piper Sandler

Why Are Myriad Genetics (MYGN) Shares Soaring Today

StockStory

3 months ago

Why Are Myriad Genetics (MYGN) Shares Soaring Today

MT Newswires

3 months ago

Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory

3 months ago

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Simply Wall St.

4 months ago

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Argus Research

4 months ago

MYGN: Lowering target price to $8.00

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

StockStory

4 months ago

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

GlobeNewswire

4 months ago

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

4 months ago

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Argus Research

4 months ago

MYGN: Lowering target price to $9.00

Why Myriad Genetics (MYGN) Shares Are Plunging Today

StockStory

4 months ago

Why Myriad Genetics (MYGN) Shares Are Plunging Today

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

Insider Monkey

4 months ago

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

MT Newswires

4 months ago

UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating

MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Zacks

4 months ago

MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Myriad Genetics Inc Earnings Call

MT Newswires

4 months ago

Myriad Genetics Appoints Sam Raha as Chief Executive

MT Newswires

4 months ago

Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated

Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

4 months ago

Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

4 months ago

Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Zacks

4 months ago

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Associated Press Finance

4 months ago

Myriad: Q4 Earnings Snapshot

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

GlobeNewswire

4 months ago

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

StockStory

4 months ago

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

GlobeNewswire

4 months ago

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Argus Research

4 months ago

MYGN: Raising target price to $12.00

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

GlobeNewswire

4 months ago

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

StockStory

4 months ago

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

MYGN Stock Might Rise on Collaboration With CancerCARE

Zacks

4 months ago

MYGN Stock Might Rise on Collaboration With CancerCARE

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

GlobeNewswire

4 months ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

MT Newswires

5 months ago

Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

GlobeNewswire

5 months ago

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

GlobeNewswire

5 months ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Argus Research

5 months ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

GlobeNewswire

5 months ago

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Argus Research

5 months ago

MYGN: What does Argus have to say about MYGN?

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

Insider Monkey

5 months ago

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

MYGN Stock Gains Following the Launch of Know More Sooner

Zacks

5 months ago

MYGN Stock Gains Following the Launch of Know More Sooner

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

GlobeNewswire

5 months ago

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Argus Research

5 months ago

MYGN: Rating decreased to a SELL

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

GlobeNewswire

5 months ago

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

MT Newswires

5 months ago

Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance

Share on Social Networks: